The findings support the idea that a rational, low-dose approach targeting 25%–50% inhibition of BACE1 could offer safe and promising therapeutic interventions if initiated at the early preclinical stage of AD with monitoring of cognitive function and biomarkers relevant to efficacy and side effects (Ohno, 2024, 2025). The gene discussed is BACE1; the disease is Alzheimer disease.